A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with &lt;i&gt;nab&lt;/i&gt;-Paclitaxel at a Single Institution

Jennifer L. Spratlin; Michael B. Saywer; Michael P. Kolinsky

文献导航

搜索文章

搜索思路

钛学术文献服务平台 \
学术期刊 \
综合期刊 \
其它期刊 \
癌症治疗（英文）期刊 \
A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with <i>nab</i>-Paclitaxel at a Single Institution

A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with <i>nab</i>-Paclitaxel at a Single Institution

作者：

Jennifer L. Spratlin Michael B. Saywer Michael P. Kolinsky

基本信息来源于合作网站，原文需代理用户跳转至来源网站获取

NAB-PACLITAXEL

Pancreatic

Cancer

CHOLANGIOCARCINOMA

Case

Series

摘要：

Background: Locally advanced or metastatic pancreatic cancer patients have a poor prognosis with median survival less than 12 months. Nanoparticle albumin bound (nab)-paclitaxel is a novel agent that has demonstrated antitumor effects in cancers that overexpress the albumin binding protein SPARC (secreted protein acidic and rich in cysteine), which includes pancreatic cancer. A recent phase III trial comparing nab-paclitaxel and gemcitabine to gemcitabine alone demonstrated a survival advantage in patients with previously untreated metastatic pancreatic cancer. Here we present our local experience with this drug in patients with gastrointestinal malignancies. Methods: Patients treated with nab-paclitaxel for gastrointestinal malignancies at the Cross Cancer Institute in Edmonton, Alberta, Canada were identified and these patient’s medical records were interrogated for data. Results: Three patients with pancreatic cancer and two with cholangiocarcinoma have been treated with nab-paclitaxel at the Cross Cancer Institute. Three patients achieved stable disease, while one had a partial response, and one had progressive disease after the first assessment. Median time to progression was 3.7 months. Median overall survival (OS) was 32.5 months. Median OS from initiation of nab-paclitaxel was 7.2 months. Patients tolerated treatment with nab-paclitaxel well with only one patient requiring treatment modification due to neutropenia. Conclusion: The experience at this single center supports published evidence that nab-paclitaxel is a safe and effective therapy in pancreatic cancer, but also suggests that it may have activity in cholangiocarcinoma, which to our knowledge is the first published evidence of this in humans.

内容分析

关键词云

关键词热度

相关文献

推荐文献

根据相关规定，获取原文需跳转至原文服务方进行注册认证身份信息

完成下面三个步骤操作后即可获取文献，阅读后请点击下方页面【继续获取】按钮

钛学术文献服务平台

学术出版新技术应用与公共服务实验室出品

原文合作方

获取文献流程

1.访问原文合作方请等待几秒系统会自动跳转至登录页，首次访问请先注册账号，填写基本信息后，点击【注册】

2.注册后进行实名认证，实名认证成功后点击【返回】

3.检查邮箱地址是否正确，若错误或未填写请填写正确邮箱地址，点击【确认支付】完成获取，文献将在1小时内发送至您的邮箱

*若已注册过原文合作方账号的用户，可跳过上述操作，直接登录后获取原文即可

点击【获取原文】按钮，跳转至合作网站。

首次获取需要在合作网站进行注册。

注册并实名认证，认证后点击【返回】按钮。

确认邮箱信息，点击【确认支付】，订单将在一小时内发送至您的邮箱。

* 若已经注册过合作网站账号，请忽略第二、三步，直接登录即可。

期刊分类
期刊（年）
期刊（期）
期刊推荐

其它

癌症治疗（英文）2021 癌症治疗（英文）2020 癌症治疗（英文）2019 癌症治疗（英文）2018 癌症治疗（英文）2017 癌症治疗（英文）2015 癌症治疗（英文）2014

癌症治疗（英文）2014年第9期癌症治疗（英文）2014年第8期癌症治疗（英文）2014年第7期癌症治疗（英文）2014年第6期癌症治疗（英文）2014年第5期癌症治疗（英文）2014年第4期癌症治疗（英文）2014年第3期癌症治疗（英文）2014年第2期癌症治疗（英文）2014年第10期癌症治疗（英文）2014年第1期

按字母查找期刊：

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
其他

联系合作广告推广: shenyukuan@paperpass.com

篇名	A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with <i>nab</i>-Paclitaxel at a Single Institution
来源期刊	癌症治疗(英文)	学科	医学
关键词	NAB-PACLITAXEL Pancreatic Cancer CHOLANGIOCARCINOMA Case Series
年，卷（期）	2014,（6）	所属期刊栏目
研究方向		页码范围	605-610
页数	6页	分类号	R73
字数		语种
DOI

A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with <i>nab</i>-Paclitaxel at a Single Institution

A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with &lt;i&gt;nab&lt;/i&gt;-Paclitaxel at a Single Institution

A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with <i>nab</i>-Paclitaxel at a Single Institution